Plimoth Trust Co. LLC Has $550,000 Holdings in Danaher Co. (NYSE:DHR)

Plimoth Trust Co. LLC grew its position in shares of Danaher Co. (NYSE:DHR) by 16.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,978 shares of the conglomerate’s stock after acquiring an additional 280 shares during the period. Plimoth Trust Co. LLC’s holdings in Danaher were worth $550,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Swedbank AB acquired a new stake in shares of Danaher in the first quarter worth $676,545,000. TD Asset Management Inc boosted its holdings in shares of Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the last quarter. Finally, Castle Hook Partners LP bought a new position in Danaher in the 1st quarter worth $98,913,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Bank of America raised their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Evercore ISI increased their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Price Performance

Shares of DHR traded down $2.29 during mid-day trading on Monday, reaching $272.09. The company had a trading volume of 2,351,047 shares, compared to its average volume of 2,716,144. The company’s 50-day moving average is $270.72 and its 200-day moving average is $260.13. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market capitalization of $201.53 billion, a P/E ratio of 46.10, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business earned $2.05 earnings per share. The business’s revenue was down 2.9% on a year-over-year basis. On average, equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.